| Issue Type | XXXX |
|---|---|
| Country | Israel |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2028-03-01 |
| Par Value | 200000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 1246.35 |
| Coupon | 6.75 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 1246.345 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This Teva Pharmaceutical Finance Netherlands III B.V. corporate note has a X.X % fixed rate coupon paid on a XXXX basis. It was issued on MAR 12, 2000 with an issue size of XXX million USD and matures on DEC 9, 2000 with a last coupon date of FEB 28, 2020. |
Teva Pharmaceutical Finance Netherlands III B.V., founded in the Netherlands, serves as a financing entity primarily for its parent company, Teva Pharmaceutical Industries Ltd., which is headquartered in Israel. The company focuses on raising capital through bond issuances to support Teva's global operations and strategic initiatives in the pharmaceutical sector.